Cambridge, MA, September 9, 2002 - Therion Biologics announces the expansion of its management team with the addition of George A. Eldridge as Chief Financial Officer; Suman Patel, Ph.D. as Vice President, Quality; and Erin E. Quinn as Vice President, Human Resources. Mr. Eldridge joins Therion from Curis, Inc., bringing demonstrated success in financial strategy and fundraising, while Dr. Patel, previously of Millennium Pharmaceuticals, Inc., brings extensive analytical development and quality control leadership. Ms. Quinn, most recently with ViaCell, Inc., adds broad experience in developing and implementing strategic human resources programs supporting corporate strategy and growth.

�As Therion continues to advance its lead cancer vaccine programs in the clinic, it is imperative that we build the management infrastructure to support our activities towards product commercialization,� stated Mark Leuchtenberger, President and Chief Executive Officer of Therion. �George comes to Therion with a solid track record in leading successful financing activities, expertise that will become increasingly important as we evaluate future fundraising options. Suman�s experience in product development and manufacturing operations will be an asset to Therion as we plan for advanced clinical trials in our lead program areas. In addition, Erin brings valuable experience in developing and managing a strong corporate culture, and recruitment and retention strategies that are essential to retaining and attracting talented professionals dedicated to leading Therion into its next phase of development.�

While with Curis and, prior to merging, Ontogeny, Inc., Mr. Eldridge was responsible for securing corporate investments and for raising over $100 million in three institutional equity offerings. He also led the successful integration of all departments in the three-way merger between Creative BioMolecules, Ontogeny and Reprogenesis that created Curis in August of 2000. Prior to joining Curis, Mr. Eldridge was Chief Financial Officer for Boston Life Sciences, Inc., and was an investment banker at Kidder Peabody & Co., Inc. Mr. Eldridge earned an M.B.A. from the University of Chicago, and a B.A. in government and economics from Dartmouth College.

Dr. Patel joins Therion from Millennium Pharmaceuticals where he served as Senior Director, Quality Assurance and Quality Control, and was responsible for devising assurance and quality strategies and business plans. He also provided chemistry manufacturing and controls (CMC) support around product marketing and completed a major quality assurance/control organization development for the company. With over 17 years of biopharmaceutical and pharmaceutical experience, Dr. Patel also held senior management positions at Biogen, Inc., Schering-Plough Research Institute, and Eastman Kodak Company. Dr. Patel received a B.S. in zoology, an M.S. in physiological chemistry and reproductive physiology, and a Ph.D. from the University of Baroda, India.

As Director of Human Resources for ViaCell, Ms. Quinn developed a strategic growth plan and formulated progressive recruitment strategies and reward systems as ViaCell�s work force grew by more than 300 percent. Ms. Quinn also established a company-wide communications strategy and performance management initiative, which established the foundation of a high-performing corporate culture. Before joining ViaCell, she was a Human Resources Business Partner at Genzyme Corporation for the Therapeutics and International Divisions and was a Founder/Partner of Outsourcing Solutions, Inc., a human resources consulting firm. Ms. Quinn received a B.S. in business administration from Northeastern University.

About Therion Biologics Corporation
Therion Biologics Corporation develops therapeutic vaccines for cancer and preventive vaccines for AIDS. The company has three lead programs involving multiple clinical trials: PROSTVAC^®-VF/TRICOM� for prostate cancer; CEA/MUC-1-VF/TRICOM for pancreatic cancer; and VF/TRICOM for melanoma. Therion is also applying its technology platform to develop vaccines to treat breast cancer and other solid tumors. The company�s strategic partners include Aventis Pasteur, which is developing a clinical candidate for colon cancer, ALVAC-CEA/B7.1, the National Cancer Institute and a global network of leading clinical institutions. Therion is headquartered in Cambridge, Massachusetts.